Thymic Peptide Bioregulator

Vilon

Lys-Glu • KE Dipeptide

Vilon is a synthetic two-amino-acid peptide studied primarily in thymic, immune-cell, chromatin, and aging models. The mechanistic signal is interesting, but modern human outcome data and validated injectable protocols remain limited.

Thymic Research Chromatin Signaling Immune-Cell Models Healthy-Aging Research

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

Vilon

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Daily Dose

200mcg–1mg

Community research convention; no validated human dose.

Cycle

10–20 Days

Typically repeated two or three times per year.

Route

Subcutaneous injection

Commonly discussed injectable research route.

Suggested Timing

Morning / Pre-Workout

Once daily at a consistent time.

Peptide Grade

GradeB

Vilon has KE-specific chromatin and immune-cell research plus a genuinely positive niche community signal, but modern controlled human outcomes, validated injectable dosing, and long-term immune safety data remain lacking.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Vilon?

Vilon is the synthetic dipeptide Lys-Glu, also written KE. It belongs to the short peptide-bioregulator research program associated with Vladimir Khavinson and is positioned as the minimal sequence linked to thymic and immune-regulatory activity.

Laboratory studies have examined Vilon in cultured human and animal thymic cells, lymphocytes, tumor models, and aging-related chromatin systems. Proposed actions include changes in lymphocyte differentiation markers, inflammatory signaling, cell proliferation, and chromatin organization.

Those findings are mechanistic signals—not proof that injectable Vilon improves immunity, prevents illness, or changes aging outcomes in people. Much of the literature comes from a small research network, and independent modern replication is sparse.

Vilon Benefits

The most defensible use cases are research hypotheses. Direct clinical benefit remains unproven.

Thymic Signaling

Cell-culture work has explored differentiation and activation markers in thymic immune cells.

Chromatin Regulation

Small human-cell studies reported deheterochromatinization in lymphocytes from older adults.

Inflammatory Models

Preclinical work suggests context-dependent effects on immune and inflammatory signaling.

Immune Aging

Its thymic origin makes age-related immune function the central research concept, not an established outcome.

Protocol Planning

Dosing, cycling, and preparation

Vilon Dosing Protocol

No modern human dose-finding trial has established an optimal injectable dose, frequency, or cycle. The ranges below reflect community research conventions, not an approved protocol.

Standard Protocol

Dose

200mcg–1mg per day

Route

Subcutaneous injection

Cycle

10–20 days

Frequency

Once daily, often pre-workout or morning

Repeat

Every 3–6 months (2–3 cycles per year)

Practical Progression

Low

200–400mcg daily

Moderate

500–750mcg daily

Upper Convention

1mg daily

Priority

Change one variable at a time and track objective immune-health context

Vilon Reconstitution

20mg Vial

Diluent

3ml bacteriostatic water

Concentration

6.67mg/mL

Per U-100 Unit

66.7mcg

Storage

Refrigerate after reconstitution

Reconstitution Calculator

Dose Conversion

200mcg

3 units

500mcg

7.5 units

750mcg

11.25 units

1mg

15 units

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public and private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Enthusiasts describe pronounced improvements in energy, daily function, and resilience—occasionally beginning within the first few doses.
Chronic-illness and post-viral communities include strong reports of better activity tolerance and fewer crashes, although Vilon is often paired with VIP, Thymosin Alpha-1, or gut-focused peptides.
Some users credit Vilon-containing stacks with calmer immune or histamine reactivity and improved gut tolerance.
Many bioregulator users regard Vilon as a repeat-cycle staple rather than a one-time novelty, particularly when immune resilience is the goal.

Negative Reports

Some users still report no noticeable effect, especially without a defined symptom pattern or objective tracking.
The strongest success stories frequently involve stacks, making it impossible to assign the full result to Vilon.
Occasional reports include fatigue, headache, injection-site irritation, or a noticeable rise in heart rate.

Stacking & Synergy

Potential Vilon pairings and tracking context

No controlled trials validate Vilon combinations. Pairings are best treated as separate research questions, with one new variable introduced at a time.

Vilon + Thymosin Alpha-1

Immune-focused pairing. TA-1 has the stronger clinical history; Vilon adds a speculative thymic-bioregulator angle. Overlap makes response attribution difficult.

Vilon + Epitalon

Bioregulator pairing. Community protocols often combine immune-aging and circadian-longevity concepts, but no human combination data establishes added value.

Vilon + KPV

Inflammation-context pairing. KPV is discussed around inflammatory and barrier signaling; Vilon is positioned around thymic regulation. Their combined effect is unknown.

Free with login

Track in Journal

Use objective context wherever possible; Vilon’s reported effects are usually too subtle for memory alone.

Dose, timing, and cycle day.
Illness frequency, symptoms, and recovery.
Energy, sleep, and training readiness.
Other immune agents, bioregulators, and medication changes.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

Vilon Side Effects

Compound-specific human safety data are sparse. A quiet adverse-event record should not be interpreted as proof of safety.

Published Research

Small laboratory studies focus on signaling and cell behavior, not comprehensive toxicity.
No modern long-term injectable safety program or formal interaction study is available.

What Users Report

Most reports describe no obvious acute effect.
Headache, fatigue, and injection-site redness are occasionally reported.

Vilon Contraindications and Precautions

Do Not Use If You Have

Known hypersensitivity to Vilon or its components.
Pregnancy or breastfeeding, because safety data are unavailable.

Use Caution With

Autoimmune disease, immune deficiency, transplant history, or active cancer.
Immunosuppressants, biologic immune therapies, or other immune-modulating compounds.

Drug Interactions

No formal interaction studies have been conducted. Because Vilon is proposed to affect immune-cell behavior, combining it with immune-active medications creates unknown risks and confounding.

Regulatory Status

Vilon is not FDA approved for any medical indication. It has no established human therapeutic dose or approved injectable route.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Vilon is one of the more interesting bioregulators to experiment with—and the results in the community are quite positive. Our own personal experience would agree.

Feedback is strong: noticeably less DOMS (especially legs), cleaner sustained energy with zero crash mid-session, and sleep/HRV holding solid. It feels like it sharpens recovery and daily output without the usual stim jitter or fatigue. Pairing it with Pinealon + Epitalon creates a nice foundational stack—immune/thymus support plus the neural and longevity angles.

Underrated gem in the Khavinson lineup. Low-risk, high-upside for training recovery and steady energy when used short-cycle. Beats a lot of the overhyped stuff for practical gym and life performance. Solid addition to keep running periodically.